Anti-VEGF agents are currently striving to establish a prominent presence in the landscape of tumor treatment, including head and neck squamous cell carcinoma (HNSCC) [36,37] and potentially papillary thyroid carcinoma (PTC) [38]; therefore, their significance could extend to HT regimens. Here, VEGFA is linked to thyroid gland papillary carcinoma.